Second phase 3 study results for LMTX® published in the Journal of Alzheimer's Disease

TauRx Therapeutics Ltd today reported the full results from its second Phase 3 clinical study of LMTX®, the first tau aggregation inhibitor in Alzheimer's disease, published online in the Journal of Alzheimer's Disease.

What feeling does this article give you?
Joy
Disgust
Fear
Anger
Sadness

#hashtags to follow:

TauRx Therapeutics Ltd [+]    Phase 3 [+]    LMTX [+]    Alzheimer [+]    Journal of Alzheimer [+]   

More #news: